Please login to Zacks.com or register to post a comment.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Torchmark Corp. ( ( TMK - Analyst Report ) ) has announced that it is about to acquire privately-held supplemental health insurer Family Heritage Life Insurance Company of America for about $218.5 million. Torchmark’s internal funds would be utilized to finance this definitive deal.
Torchmark will market Family Heritage’s supplemental health insurance products to middle-class families via the latter’s 1200 captive sales agents. The acquisition is deemed as the best fit for Torchmark since it was aiming to grow in supplemental health insurance line of business, which provides higher margin.
Family Heritage, based in Ohio, is a company that has demonstrated strong performance with substantial premium growth. In addition to this, the company has solid underwriting margins.
The acquisition is expected to close in the early fourth quarter of 2012 and will be additive to Torchmark’s earnings immediately. Moreover, the deal would leave the free cash flow of the company unaffected.
Torchmark expects the acquisition to add 1 to 3 cents per share to its 2012 earnings and 13 to 17 cents per share to the 2013 earnings.
Late last month, the company reported second-quarter 2012 net operating income of $1.30 a share, improving 19.3% year over year. The increase was due to higher insurance underwriting income coupled with increased investment income. Lower share count compared with the year-ago period, owing to share repurchases, also buoyed the bottom line.
While releasing its second quarter earnings, Torchmark’s management announced fiscal 2012 guidance for earnings per share in the range of $5.08 – $5.26. This showed a reduction from the company’s earlier projected range of $5.10 – $5.40 per share. Nevertheless, we believe this acquision will help the company in achieving its guidance.
Torchmark, which competes with Assurant Inc. ( AIZ - Analyst Report ) , currently retains a Zacks #3 Rank, which translates into a short-term Hold rating. We are also maintaining our long-term Neutral recommendation on its shares.
Read the full Analyst Report on TMK
Read the full Analyst Report on AIZ